scispace - formally typeset
M

Maha A. El-Demellawy

Researcher at King Abdulaziz University

Publications -  21
Citations -  954

Maha A. El-Demellawy is an academic researcher from King Abdulaziz University. The author has contributed to research in topics: Nanocarriers & TBARS. The author has an hindex of 14, co-authored 20 publications receiving 756 citations.

Papers
More filters
Journal ArticleDOI

Polysubstituted pyrazoles, part 5. Synthesis of new 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylic acid hydrazide analogs and some derived ring systems. A novel class of potential antitumor and anti-HCV agents.

TL;DR: Seven compounds, namely 7a-c, 9, 11, 13 and 14, exhibited potential and broad spectrum antitumor activity against most of the tested subpanel tumour cell lines (GI50<100 microM) and particular effectiveness on the leukaemia subpanel at both the GI50 and TGI levels.
Journal ArticleDOI

Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer.

TL;DR: This combined nano‐delivery system maximized synergistic cytotoxicity of RAP and WOG in terms of tumor inhibition in MCF‐7 breast cancer cells and Ehrlich ascites tumor animal model as a result of enhanced active targeting.
Journal ArticleDOI

HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients.

TL;DR: The data indicate that certain class II alleles/haplotypes are associated with risk or protection from RHD and that these associations appear to be stronger and more consistent when analyzed in patients with relatively more homogeneous clinical manifestations.
Journal ArticleDOI

Cyanoacetic acid hydrazones of 3-(and 4-)acetylpyridine and some derived ring systems as potential antitumor and anti-HCV agents.

TL;DR: Two new acetylpyridinehydrazones derived from cyanoacetic acid hydrazide have been synthesized and nine compounds were investigated for their in‐vitro effect on the replication of hepatitis‐C virus (HCV) in HepG2 hepatocellular carcinoma cell line infected with the virus.